National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Avelumab (Bavencio®)

Avelumab (Bavencio®) is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.


NCPE Assessment Process Ongoing
Rapid review received 17/10/2017
Rapid review completed 21/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 22/11/2017
Pre-submission consultation with Applicant 11/12/2017
Submission received from Applicant 16/03/2018
Preliminary review sent to Applicant 12/07/2018
NCPE assessment re-commenced 10/08/2018
Factual accuracy sent to Applicant 06/09/2018
NCPE assessment re-commenced 20/09/2018
NCPE assessment completed 08/10/2018
NCPE assessment outcome The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.


The HSE has approved reimbursement “approval is restricted to second line” following confidential price negotiations; May 2019